Abstract
Posterior reversible encephalopathy syndrome (PRES) is an acute central nervous system disorder characterized by reversible brain vasogenic edema.
We report here a new case of a nine-year-old boy with B-cell acute lymphoblastic leukemia (B-ALL) who developed PRES secondary to induction chemotherapy including dexamethasone (dexamethasone®), vincristine (oncovin®), daunorubicin (adriblastine®) and intrathecal injection. Cerebral magnetic resonance imaging (MRI) showed high signal intensity on T2 at cortical and sub cortical region of parieto-frontal and parieto-occipital lobes. The patient was put under sodium valproate (depakine®) and we decided to continue dexamethasone (dexamethasone®) and daunorubicin (adriblastine®) injection. The MRI, after four weeks, was normal. So, we resumed vincristine (oncovin®) and we started L-asparaginase injections. Then, the outcome was favorable.
The treatment of PRES is based on the withdrawal of the triggering factor to avoid the risk of irreversible lesions. But, due to the severity of leukemia the discontinuation of chemotherapy is difficult because of the risk of disease progression.
Keywords: Chemotherapy, diagnosis, etiopathogeny, leukemia, PRES, treatment.
Current Drug Safety
Title:Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Volume: 10 Issue: 2
Author(s): Wala Ben Kridis, Moez Mdhaffer, Yosr Hentati, Fatma Kammoun, Abir Milad, Sondes Haddar, Khaireddine Ben Mahfoudh, Chahinez Triki and Moez Elloumi
Affiliation:
Keywords: Chemotherapy, diagnosis, etiopathogeny, leukemia, PRES, treatment.
Abstract: Posterior reversible encephalopathy syndrome (PRES) is an acute central nervous system disorder characterized by reversible brain vasogenic edema.
We report here a new case of a nine-year-old boy with B-cell acute lymphoblastic leukemia (B-ALL) who developed PRES secondary to induction chemotherapy including dexamethasone (dexamethasone®), vincristine (oncovin®), daunorubicin (adriblastine®) and intrathecal injection. Cerebral magnetic resonance imaging (MRI) showed high signal intensity on T2 at cortical and sub cortical region of parieto-frontal and parieto-occipital lobes. The patient was put under sodium valproate (depakine®) and we decided to continue dexamethasone (dexamethasone®) and daunorubicin (adriblastine®) injection. The MRI, after four weeks, was normal. So, we resumed vincristine (oncovin®) and we started L-asparaginase injections. Then, the outcome was favorable.
The treatment of PRES is based on the withdrawal of the triggering factor to avoid the risk of irreversible lesions. But, due to the severity of leukemia the discontinuation of chemotherapy is difficult because of the risk of disease progression.
Export Options
About this article
Cite this article as:
Kridis Ben Wala, Mdhaffer Moez, Hentati Yosr, Kammoun Fatma, Milad Abir, Haddar Sondes, Mahfoudh Ben Khaireddine, Triki Chahinez and Elloumi Moez, Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140610160851
DOI https://dx.doi.org/10.2174/1574886309666140610160851 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design New Biological Approaches in Asthma: DNA-Based Therapy
Current Medicinal Chemistry Refractory Cough as a Remote Manifestation of Retroperitoneal Liposarcoma
Current Cancer Therapy Reviews Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging Unravelling the Genetic Susceptibility to Develop Ligament and Tendon Injuries
Current Stem Cell Research & Therapy A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Editorial (Thematic Issue: Epigenetic Regulation and Human Diseases)
Current Pharmaceutical Design An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery Gene Therapy by Liver Transplantation and Single Stranded Oligonucleotides (SSOs) in Familial Amyloidotic Polyneuropathy (FAP)
Current Pharmacogenomics Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Current Pharmaceutical Design RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine